Mannatech (MTEX) Stock Price, News & Analysis

Company Overview

Mannatech, Inc. is a global health and wellness company that develops and markets a range of dietary supplements and personal care products through a direct selling business model. The company’s core focus is on glyconutrients, specialized carbohydrates believed to support cellular communication, which form the basis of many of its flagship offerings. Operating under a network marketing structure, Mannatech empowers independent associates to promote and distribute its products in markets around the world.

The company’s product portfolio includes nutritional supplements aimed at immune support, digestive health, and healthy aging, as well as skincare items designed to promote hydration and skin vitality. Among its most recognized products is Ambrotose®, a patented blend of plant-derived saccharides. Mannatech has also expanded into targeted formulations for children’s health, weight management, and topical therapies, leveraging its nutrition science platform to address a variety of wellness needs.

Since its founding in 1993 in the United States, Mannatech has extended its reach to more than 30 countries across North America, Europe, Asia-Pacific, and Latin America. Headquartered in Flower Mound, Texas, the company maintains regional offices and distribution centers to support its independent sales force. Through ongoing collaborations with academic institutions and research partners, Mannatech invests in clinical studies to validate the efficacy and safety of its products, reinforcing its commitment to science-backed innovation.

Leadership at Mannatech is led by President and Chief Executive Officer Roy Wezelman, who brings extensive experience in direct selling and international operations. The company is guided by a board of directors with backgrounds in nutrition science, regulatory affairs, and global business development. Mannatech continues to pursue growth by expanding its product pipeline, enhancing digital platforms for associate training, and entering new markets where demand for nutritional products is on the rise.

Key Stats

• Today's Range: $8.67 to $9.57
• 50-Day Range: $7.58 to $9.99
• 52-Week Range: $7.05 to $16.49
• Volume: 11,493 shs
• Average Volume: 12,271 shs
• Market Capitalization: $18.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mannatech Stock Analysis - MarketRank™

Mannatech scored higher than 8% of companies evaluated by MarketBeat, and ranked 902nd out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mannatech.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mannatech is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mannatech is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mannatech has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.43% of the float of Mannatech has been sold short.

Short Interest Ratio / Days to Cover

Mannatech has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mannatech has recently increased by 53.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mannatech does not currently pay a dividend.

Dividend Growth

Mannatech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.43% of the float of Mannatech has been sold short.

Short Interest Ratio / Days to Cover

Mannatech has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mannatech has recently increased by 53.41%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: -0.50

News Sentiment

Mannatech has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Mannatech this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for MTEX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mannatech insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.50% of the stock of Mannatech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.98% of the stock of Mannatech is held by institutions.

MTEX Stock Analysis - Frequently Asked Questions

How have MTEX shares performed this year?

Mannatech's stock was trading at $13.43 on January 1st, 2025. Since then, MTEX shares have decreased by 28.7% and is now trading at $9.57.

How were Mannatech's earnings last quarter?

Mannatech, Incorporated (NASDAQ:MTEX) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($2.27) EPS for the quarter. The company earned $25.68 million during the quarter. Mannatech had a negative net margin of 3.46% and a negative trailing twelve-month return on equity of 48.60%.

Who are Mannatech's major shareholders?

Top institutional shareholders of Mannatech include Bridgeway Capital Management LLC (1.52%). Insiders that own company stock include Larry A Jobe, Kevin Andrew Robbins and Alfredo Bala.
View institutional ownership trends.

How do I buy shares of Mannatech?

Shares of MTEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mannatech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mannatech investors own include CrowdStrike (CRWD), Walt Disney (DIS), Herbalife (HLF), Roku (ROKU), Alibaba Group (BABA), Enphase Energy (ENPH) and Enterprise Products Partners (EPD).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/07/2025
• Next Earnings (Estimated): 11/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MTEX
• CIK: 1056358
• Web: www.mannatech.com
• Phone: (972) 471-7400
• Fax: 972-471-8117
• Employees: 250
• Year Founded: 1994

Profitability

• EPS (Trailing Twelve Months): ($2.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.49 million
• Net Margins: -3.46%
• Pretax Margin: -3.06%
• Return on Equity: -48.60%
• Return on Assets: -10.70%

Debt

• Debt-to-Equity Ratio: 0.58
• Current Ratio: 1.11
• Quick Ratio: 0.49

Sales & Book Value

• Annual Sales: $117.87 million
• Price / Sales: 0.15
• Cash Flow: $2.14 per share
• Price / Cash Flow: 4.48
• Book Value: $4.57 per share
• Price / Book: 2.09

Miscellaneous

• Outstanding Shares: 1,900,000
• Free Float: 1,112,000
• Market Cap: $18.18 million
• Optionable: Not Optionable
• Beta: 0.83